Brokers Offer Predictions for EYPT FY2025 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of EyePoint Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim anticipates that the company will post earnings per share of ($2.49) for the year. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.06). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The business had revenue of $10.52 million for the quarter, compared to analyst estimates of $12.35 million.

Other analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Chardan Capital lifted their price objective on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Robert W. Baird reduced their price objective on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, November 11th. Scotiabank assumed coverage on EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price target for the company. Finally, Citigroup assumed coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price target for the company. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $26.63.

EyePoint Pharmaceuticals Trading Up 14.3 %

Shares of EYPT stock opened at $8.72 on Wednesday. The business’s 50 day moving average is $8.20 and its two-hundred day moving average is $8.94. EyePoint Pharmaceuticals has a twelve month low of $6.90 and a twelve month high of $30.99. The company has a market capitalization of $595.14 million, a P/E ratio of -4.36 and a beta of 1.49.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Greenwich Wealth Management LLC lifted its stake in shares of EyePoint Pharmaceuticals by 8.3% in the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after acquiring an additional 900 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of EyePoint Pharmaceuticals by 68.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after acquiring an additional 4,172 shares in the last quarter. Cyndeo Wealth Partners LLC raised its stake in EyePoint Pharmaceuticals by 35.5% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company’s stock valued at $127,000 after buying an additional 4,450 shares in the last quarter. Fiera Capital Corp raised its stake in EyePoint Pharmaceuticals by 0.9% during the second quarter. Fiera Capital Corp now owns 677,038 shares of the company’s stock valued at $5,890,000 after buying an additional 5,920 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in EyePoint Pharmaceuticals by 5.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock valued at $1,141,000 after buying an additional 7,967 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.